Peter Loftus is a reporter at The Wall Street Journal. He covers a range of topics including pharmaceuticals, medical devices, and healthcare, with a focus on finance and healthcare technology. His work has been featured in The Wall Street Journal, MarketWatch, LiveMint, Yahoo Finance, and Magzter.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Peter Loftus' coverage predominantly focuses on the health and healthcare industry, with a specific emphasis on pharmaceutical companies, drug approvals, shortages, leadership changes within these organizations, and medical devices. His articles often cite data or refer to press releases and government announcements.
Given his focus on the pharmaceutical industry and healthcare sector, he is likely to be interested in pitches related to exclusive insights from experts within these industries regarding new drugs (especially weight-loss drugs and diabetes drugs), company strategies for overcoming shortages or handling leadership changes. Furthermore, offering access to credible data or analysis is crucial when pitching potential topics of interest.
Since Peter's geographic focus is not specified but considering that many of the covered companies are based in the US such as Eli Lilly & Co., Johnson & Johnson among others; relevant sources should have knowledge about these companies' operations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
President Trump's tariffs are eating into profits at GE Healthcare, the large maker of imaging and other medical equipment that was spun out of General Electric in 2023.
By: Jared S. Hopkins|7317, Jared S. Hopkins, Peter Loftus, Jared S. Hopkins|Peter Loftus
Executive order says if companies and the government don’t align on tying U.S. drug prices to other countries, the administration will impose its own plan.
By: Peter Loftus
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.
By: Dominic Chopping, Peter Loftus
Ozempic maker Novo Nordisk pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price
By: Peter Loftus
Anti-obesity drugs are showing promise for an ever-expanding list of diseases
GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.
By: Peter Loftus
British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we have what it will take to navigate and mitigate,” GSK Chief Executive Emma Walmsley said at The Wall Street Jou
Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.
By: Noemie Bisserbe, Peter Loftus
In 2023, Novo Nordisk was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy.Today, the Danish
British drugmaker GSK is preparing for potential new U.S. tariffs on its medicines and can handle the challenge, the company’s leader said Wednesday. “I would say we’ve been preparing, we have what it will take to navigate and mitigate,” GSK Chief Executive Emma Walmsley said at our Future of Everything conference in New York. The Trump administration is conducting an investigation that could result in new pharmaceutical-specific tariffs, which would add to the industry’s cost because a significant portion of manufacturing is outside the U.S.
(833) 317-6278 
